Corporate Board Profile
Tech Score: 0/100
| Filing Date | Source Excerpt |
|---|---|
| 2016-05-02 | The Company 27s Compensation Committee consists of directors Richard F. Pops, George J. Morrow, and Joseph Mollica, Ph.D. ... 2015 Director Compensation ... Gary A. Lyons ... $55,000 Fees Earned or Paid in Cash ... $702,185 Option Awards ... $757,185 Total |
| 2017-04-21 | Gary A. Lyons has served on the Board of Directors since February 1993. He is a member of the Science and Medical Technology Committee. Director Compensation Table shows total compensation of $456,992 for 2016. |
| 2018-04-04 | The continued service of Gary A. Lyons on the Companys Board of Directors is based on Mr. Lyons extensive business development and corporate governance experience and, as the Companys former Chief Executive Officer, his in-depth understanding of the Companys product candidates, management and culture. The Companys Science and Medical Technology Committee consists of directors Gary A. Lyons, William H. Rastetter, Ph.D. and Alfred W. Sandrock, Jr. M.D., Ph.D. The following table sets forth the compensation paid by the Company for the fiscal year ended December 31, 2017 to the directors of the Company named below: Gary A. Lyons: Fees Earned or Paid in Cash $55,000, Option Awards $442,950, Total $497,950. |
| 2019-04-17 | The Company 2018 compensation for the Company 2018 to the directors of the Company named below: Gary A. Lyons 57,500 655,250 712,750 |
| 2020-04-09 | Gary A. Lyons has served on the Board of Directors since joining Neurocrine Biosciences in February 1993. Mr. Lyons served as the President and Chief Executive Officer of the Company from February 1993 through January 2008. ... Mr. Lyons is a member of the Board of Directors of Brickell Biotech, Inc., a biotechnology company focused on dermatology, and Novus Therapeutics, Inc., a biotechnology company focused on ear, nose and throat therapies. ... Mr. Lyons holds a B.S. in marine biology from the University of New Hampshire and an M.B.A. from Northwestern University’s J.L. Kellogg Graduate School of Management. |
| 2022-04-07 | Gary A. Lyons has served on the Board of Directors since joining Neurocrine Biosciences in February 1993. ... The Company’s Nominating/Corporate Governance Committee consists of directors Stephen A. Sherwin, M.D., Johanna Mercier, George J. Morrow, and Leslie V. Norwalk, with Ms. Norwalk serving as the Nominating/Corporate Governance Committee Chair. ... For 2021, directors who are not employees of the Company earned a $60,000 annual cash retainer. ... The following table sets forth the compensation earned for the fiscal year ended December 31, 2021 by the directors of the Company named below: Gary A. Lyons $60,000 fees earned in cash and $400,003 option awards totaling $460,003. |
| 2023-04-05 | Gary A. Lyons has served on the Board of Directors since joining Neurocrine Biosciences in February 1993. Mr. Lyons served as the President and Chief Executive Officer of the Company from February 1993 through January 2008. |
| 2024-04-10 | Gary A. Lyons has served on the Board of Directors since joining Neurocrine Biosciences in February 1993. ... Mr. Lyons is currently the Chairman of the Board of Directors of Travere Therapeutics, a publicly traded ultra-orphan disease commercial-stage company, and serves as a director of Rigel Pharmaceuticals, Inc., a publicly traded biotechnology company focused on developing drugs for the treatment of inflammatory/autoimmune and metabolic diseases. ... The Company’s Compensation Committee consists of directors George J. Morrow, Richard F. Pops, and Shalini Sharp, with Mr. Pops serving as the Compensation Committee Chair. ... In January 2024, the Board formed the Science and Medical Technology Committee, which provides oversight of significant scientific judgments relating to the Company’s research and development, including clinical development, activities, portfolio, and potential business development transactions. The Science and Medical Technology Committee consists of directors Stephen A. Sherwin, M.D., William H. Rastetter, Ph.D., Gary A. Lyons, and Richard F. Pops, with Dr. Sherwin serving as the Science and Medical Technology Committee Chair. ... For fiscal 2023, directors who are not employees of the Company earned a $60,000 annual cash retainer. ... For fiscal 2023, on the date of the 2023 Annual Meeting of Stockholders, each continuing non-employee director received an annual equity award with an approximate grant date value of $400,000. ... The following table sets forth the compensation earned for the fiscal year ended December 31, 2023 by the directors of the Company named below: ... Gary A. Lyons $60,000 cash fees, $200,043 option awards, $200,067 stock awards, total $460,110. |
| Filing Date | Source Excerpt |
|---|---|
| 2014-06-12 | Mr. Lyons holds a B.S. in marine biology from the University of New Hampshire and an M.B.A. from Northwestern University’s J.L. Kellogg Graduate School of Management. Mr. Lyons qualifications to sit on our Board include his executive experience working with life sciences companies, his extensive experience in pharmaceutical business development, his knowledge, understanding and experience in the regulatory development and approval process and his service on other public company boards and committees. |
| 2014-11-24 | Gary A. Lyons is listed as a director, but no software-related technical skills are described. |
| 2015-07-02 | Gary A. Lyons has served as a Director of the Company since October 2013. Mr. Lyons has served on the Board of Directors of Neurocrine Biosciences since 1993 and as the President and Chief Executive Officer of Neurocrine from 1993 through January 2008. Prior to joining Neurocrine Biosciences, Mr. Lyons held a number of senior management positions at Genentech, Inc., including Vice President of Business Development and Vice President of Sales. Mr. Lyons currently is the Chairman of the Board of Directors for Rigel Pharmaceuticals, Inc. and serves on the Board of Vical Incorporated, KaloBios Pharmaceuticals, Inc. and Retrophin. Mr. Lyons was previously a director of PDL BioPharma, Inc., Poniard Pharmaceuticals, Inc., Neurogesx and Facet Biotech Corporation. Mr. Lyons holds a B.S. in marine biology from the University of New Hampshire and an M.B.A. from Northwestern University’s J.L. Kellogg Graduate School of Management. Mr. Lyons qualifications to sit on our Board include his executive experience working with life sciences companies, his extensive experience in pharmaceutical business development, his knowledge, understanding and experience in the regulatory development and approval process and his service on other public company boards and committees. |
| 2016-03-15 | Gary A. Lyons has served as a Director of the Company since October 2013. Mr. Lyons has served on the Board of Directors of Neurocrine Biosciences since 1993 and served as the President and Chief Executive Officer of Neurocrine from 1993 through January 2008. Prior to joining Neurocrine Biosciences, Mr. Lyons held a number of senior management positions at Genentech, Inc., including Vice President of Business Development and Vice President of Sales. Mr. Lyons currently is the Chairman of the Board of Directors for Rigel Pharmaceuticals, Inc. and serves on the Board of Vical Incorporated and Retrophin. Mr. Lyons was previously a director of PDL BioPharma, Inc., Poniard Pharmaceuticals, Inc., Neurogesx, KaloBios Pharmaceuticals, Inc. and Facet Biotech Corporation. Mr. Lyons holds a B.S. in marine biology from the University of New Hampshire and an M.B.A. from Northwestern University's J.L. Kellogg Graduate School of Management. |
| 2017-04-10 | Gary A. Lyons has served on our Board since October 2013. Mr. Lyons has served on the Board of Neurocrine Biosciences, Inc., or Neurocrine, since 1993 and served as the President and Chief Executive Officer of Neurocrine from 1993 through January 2008. Prior to joining Neurocrine, Mr. Lyons held a number of senior management positions at Genentech, Inc., including Vice President of Business Development and Vice President of Sales. Mr. Lyons has served on the Boards of Rigel Pharmaceuticals, Inc., a publicly-held biotechnology company, since October 2005 (and as Chairman since November 2014); Vical Incorporated, a publicly-held biopharmaceutical company, since 1997; and Retrophin, Inc., a publicly-held biopharmaceutical company, since 2014 (and as Chairman since May 2016). Mr. Lyons was previously a director of PDL BioPharma, Inc., Poniard Pharmaceuticals, Inc., Neurogesx, KaloBios Pharmaceuticals, Inc. and Facet Biotech Corporation. Mr. Lyons holds a B.S. in Marine Biology from the University of New Hampshire and an M.B.A. from Northwestern University’s J.L. Kellogg Graduate School of Management. |
| 2018-04-06 | Mr. Lyons holds a B.S. in Marine Biology from the University of New Hampshire and an M.B.A. from Northwestern University’s J.L. Kellogg Graduate School of Management. Mr. Lyons’ qualifications to sit on our Board include his executive experience working with life sciences companies, his extensive experience in pharmaceutical business development, his knowledge, understanding and experience in the regulatory development and approval process and his service on other public company boards and committees. |
| Filing Date | Source Excerpt |
|---|---|
| 2006-04-25 | Gary A. Lyons, age 55, joined us as a director in October 2005. Mr. Lyons has served as Chief Executive Officer and as a member of the board of directors of Neurocrine Biosciences, Inc., a biopharmaceutical company, since 1993. ... Mr. Lyons currently serves on the board of directors of Vical, Inc. |
| 2008-04-08 | Gary A. Lyons, age 57, joined us as a director in October 2005. ... The Compensation Committee comprises three directors: Drs. Moos and Deleage and Mr. Lyons. ... The Compensation Committee met five times during fiscal year 2007. ... The following table shows for the fiscal year ended December 31, 2007 certain information with respect to the compensation of all non-employee directors of the Company: Gary A. Lyons $45,500 Fees Earned or Paid in Cash, $108,216 Option Awards, Total $153,716. |
| 2009-04-15 | Gary A. Lyons, age 58, joined us as a director in October 2005. ... The following three directors are the members of the Compensation Committee: Drs. Moos and Deleage and Mr. Lyons, all of whom were on the Compensation Committee for all of fiscal year 2008. ... For services provided in 2008, each non-employee director of Rigel received a yearly retainer of $30,000, ... In the fiscal year ended December 31, 2008, the total cash compensation earned by non-employee directors was $214,533. |
| 2011-04-04 | Gary A. Lyons, age 60, joined us as a director in October 2005. The Board concluded that Mr. Lyons continues to be a valuable member of the Board in part due to his extensive experience negotiating and developing collaborative relationships, his sales expertise and his track record of assessing the market for pharmaceutical candidates, all of which are key to the success of our business. ... The following table shows the compensation of all non-employee directors of the Company for the fiscal year ended December 31, 2010: Gary A. Lyons $48,500 Option Awards $75,390 Total $123,890 |
| 2012-04-12 | Gary A. Lyons, age 61, joined us as a director in October 2005. ... The Board has four standing committees: ... Audit Committee, Compensation Committee, Finance Committee ... The following three directors are the members of the Finance Committee: Messrs. Gower and Lyons and Dr. Sherwin. ... The following three directors are the members of the Compensation Committee: Mr. Lyons and Drs. Moos and Ringrose. ... The following table shows the compensation of all non-employee directors of the Company for the fiscal year ended December 31, 2011: ... Gary A. Lyons ... Total $152,549. |
| 2013-04-03 | Gary A. Lyons, age 62, joined us as a director in October 2005. The Board concluded that Mr. Lyons should continue to serve as a member of the Board in part due to his extensive experience negotiating and developing collaborative relationships, his sales expertise and his track record of assessing the market for pharmaceutical candidates, all of which are key to the success of our business. ... The following table shows the compensation of all non-employee directors of the Company for the fiscal year ended December 31, 2012: Bradford S. Goodwin 67,000 76,760 143,760 Gary A. Lyons 65,000 76,760 141,760 Walter H. Moos, Ph.D. 65,000 76,760 141,760 Hollings C. Renton 57,000 76,760 133,760 Peter S. Ringrose, Ph.D. 67,500 76,760 144,260 Stephen A. Sherwin, M.D. 72,000 76,760 148,760 |
| 2014-04-08 | Gary A. Lyons, age 63, joined us as a director in October 2005. The Board concluded that Mr. Lyons should continue to serve as a member of the Board in part due to his extensive experience negotiating and developing collaborative relationships, his sales expertise and his track record of assessing the market for pharmaceutical candidates, all of which are key to the success of our business. ... Mr. Lyons was appointed to the Audit Committee effective March 28, 2014. ... On May 15, 2013, pursuant to the Directors' Plan, we granted options to purchase 15,000 shares of common stock to Gary A. Lyons, each at an exercise price of $4.87 per share. These options vest in 12 equal monthly installments beginning on the grant date. ... The following table shows the compensation of all non-employee directors of the Company for the fiscal year ended December 31, 2013: Gary A. Lyons Fees Earned or Paid in Cash ($) 65,000 Option Awards ($) 51,477 Total ($) 116,477 |
| 2015-03-30 | Gary A. Lyons, age 64, joined us as a director in October 2005. ... The Board has an independent chair, Mr. Lyons, who has authority, among other things, to call and preside over Board meetings, including meetings of the independent directors, to set meeting agendas and to determine materials to be distributed to the Board. ... Mr. Lyons was appointed to the Audit Committee effective March 30, 2014. ... Mr. Lyons was the Chair of the Compensation Committee for all of 2014 and the first quarter of 2015. ... The following table shows the compensation of all non-employee directors of the Company for the fiscal year ended December 31, 2014: ... Gary A. Lyons 94,000 70,326 164,326 ... |
| 2016-03-28 | Gary A. Lyons, age 65, joined us as a director in October 2005. ... Mr. Lyons was replaced by Mr. Katkin on the Audit Committee August 25, 2015. ... The following table shows the compensation of all non-employee directors of the Company for the fiscal year ended December 31, 2015: ... Gary A. Lyons Fees Earned or Paid in Cash $110,250, Option Awards $158,400, Total $268,650. |
| 2017-03-29 | Gary A. Lyons, age 65, joined us as a director in October 2005 and was appointed Chairman of the Board in January 2016. ... Mr. Lyons was selected to serve as a member of the Board in part due to his extensive experience ... The following table shows the compensation of all non-employee directors of the Company for the fiscal year ended December 31, 2016: Gary A. Lyons Fees Earned or Paid in Cash $100,000, Option Awards $57,148, Total $157,148. |
| 2018-04-04 | Gary A. Lyons, age 66, joined us as a director in October 2005 and was appointed Chairman of the Board in November 2014. ... Mr. Lyons joined the Audit Committee on May 11, 2017, effective upon Dr. Sherwin's resignation on May 11, 2017, and resigned his position on the Audit Committee upon the acceptance of Mr. Lapointe's appointment to the Board and the Audit Committee. ... The following table shows the compensation of all non-employee directors of the Company for the fiscal year ended December 31, 2017: Gary A. Lyons Fees Earned or Paid in Cash $109,000 Option Awards $64,708 Total $173,708. |
| 2019-04-09 | Gary A. Lyons, age 67, joined us as a director in October 2005 and was appointed Chairman of the Board in November 2014. ... The following three directors are the current members of the Audit Committee: Mr. Goodwin, Mr. Katkin and Mr. Lapointe. ... The following three directors are the members of the Compensation Committee: Mr. Lyons, Mr. Katkin and Dr. Moos. ... The following three directors were members of the Finance Committee for all of 2018: Mr. Lyons, Mr. Rodriguez and Mr. Goodwin. ... The following table shows the compensation of all non-employee directors of the Company for the fiscal year ended December 31, 2018: Gary A. Lyons 105,000 fees earned in cash, 103,664 option awards, total 208,664. |
| 2020-04-01 | Gary A. Lyons, age 68, joined us as a director in October 2005 and was appointed Chairman of the Board in November 2014. ... The following three directors are the current members of the Audit Committee: Mr. Goodwin, Mr. Katkin and Mr. Lapointe. ... The following three directors are the members of the Compensation Committee: Dr. Moos, Mr. Lyons and Mr. Katkin. ... The following three directors were members of the Finance Committee for all of 2019: Mr. Goodwin, Mr. Lyons and Mr. Rodriguez. ... For services provided in 2019, each non-employee director received, paid on a quarterly basis for quarters served, a yearly retainer of $50,000. ... The following table shows the compensation of all non-employee directors of the Company for the fiscal year ended December 31, 2019: Gary A. Lyons Fees Earned or Paid in Cash $105,000, Option Awards $22,917, Total $127,917. |
| 2021-04-06 | Gary A. Lyons, age 69, was named Rigel’s Chairman of the Board in November 2014, having joined us as a director in October 2005. ... The following three directors are the members of the Compensation Committee: Dr. Moos, Mr. Lyons and Mr. Katkin. ... The following three directors were members of the Finance Committee for all of 2020: Mr. Goodwin, Mr. Lyons and Mr. Rodriguez. ... The following table shows the compensation of all non-employee directors of the Company for the fiscal year ended December 31, 2020: Gary A. Lyons Fees Earned or Paid in Cash $105,000, Option Awards $62,695, Total $167,695. |
| 2023-04-14 | Gary A. Lyons, age 71, joined us as a director in October 2005 and served as Rigel’s Chairman of the Board from November 2014 until March 2022. ... The Board concluded that Mr. Lyons should continue to serve as a member of the Board in part due to his extensive experience negotiating and developing collaborative relationships, his sales expertise and his track record of assessing the market for pharmaceutical candidates, all of which are key to the success of our business. ... The following directors are currently members of the Compensation Committee: Mr. Lyons ... The following directors currently serve on the Finance Committee: Mr. Lyons. ... The following table shows the compensation of all non-employee directors of the Company for the fiscal year ended December 31, 2022: Gary A. Lyons Fees Earned or Paid in Cash ($) 63,750 Stock Awards ($) 50,250 Option Awards ($) 40,926 Total ($) 154,926. |
Source material: SEC submissions metadata and DEF 14A proxy filings from EDGAR. Last updated: 2026-03-22